gp91 Grans
Phase 1Biologic
gp91 Grans is one of 12 biologic programs targeting Chronic Granulomatous Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Chronic Granulomatous Disease
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Busulfex
Akero TherapeuticsPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Campath
GGenzyme, a Sanofi Company
Phase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Tociluzumab
RochePhase 2
Xeljanz
PfizerPhase 2
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Emapalumab-Izsg
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
JSP191
JJasper Therapeutics, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Granulomatous Disease1 trial
NADPH Oxidase Correction in mRNA Transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05189925·25 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for gp91 Grans. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details